Skip to content


We are advancing a pipeline of antibody-based precision radiotherapeutics based on our proprietary ROVErâ„¢ platform to tackle a variety of cancer indications with high unmet need.

Each program utilizes a ROVErâ„¢ platform antibody that binds a solid tumor target and is designed to optimize therapeutic index of therapeutic radioisotopes. Our approach also allows a corresponding imaging agent to be employed to assess healthy tissue exposure (dosimetry), measure target engagement, select the right patients and guide clinical development.


Lead Optimization
ABD-147 SCLC ABD-147
Phase: IND-Enabling
ABD-002 Undisclosed Target ABD-002
ABD-002 Undisclosed Target
Phase: Lead Optimization
ABD-003 Undisclosed Target ABD-003
ABD-003 Undisclosed Target
Phase: Lead Optimization
ABD-004 Undisclosed Target ABD-004
ABD-004 Undisclosed Target
Phase: Discovery
ABD-005 Undisclosed Target ABD-005
ABD-005 Undisclosed Target
Phase: Discovery

ABD-147 for Small Cell Lung Cancer

Delta-like ligand 3 (DLL3) is a protein in the Notch pathway, which is critical for the development and regulation of neuroendocrine versus epithelial cell differentiation in the lungs. In certain high grade neuroendocrine carcinomas including small cell lung cancer (SCLC), DLL3 is upregulated and specifically expressed at low levels on the cell surface. In contrast, DLL3 is absent or very rarely expressed on nonmalignant cells. Given the high specificity of DLL3 expression on cancer cells and the distinct mechanism of action, DLL3 represents a compelling target for treating SCLC and other DLL3+ solid tumors with targeted radiotherapy.

Our lead product candidate, ABD-147, is advancing in preclinical development with the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) expected in 2024.